cnty-101 vs cnty-813

Both cnty-101 and cnty-813 are in development for Systemic Lupus Erythematosus; R/R CD19-Positive B-Cell Malignancies.

cnty-101cnty-813
Developers11
Clinical trials10
FDA decisions00
Generic name——